Business

Around the Region

Biogen’s Hemophilia B drug advances

Biogen Idec Inc. reported Monday that the Food and Drug Administration has accepted­ its biologics license application for marketing approval for a fusion protein that would be used to treat hemophilia B.

The FDA granted the Weston company a standard review timeline, Biogen Idec added in a news release.

Advertisement

Recombinant FIXFc is the first product candidate in a new class of long-lasting clotting factor therapies being developed with the goal of reducing the burden of treatment for hemophilia B, the company said.

“We are encouraged by the FDA’s acceptance of our application, as we believe rFIXFc has the potential to transform the care of hemophilia B by ­allowing for less frequent injections and helping patients to maintain low annualized bleeding rates,” Glenn Pierce, senior vice president of Global Medical Affairs and chief medical officer of Biogen Idec’s hemophilia­ therapeutic area, said in a statement.

Get Talking Points in your inbox:
An afternoon recap of the day’s most important business news, delivered weekdays.
Thank you for signing up! Sign up for more newsletters here

“We are working with the FDA to bring the first major treatment advance for the ­hemophilia B community in 15 years.”

Globe Staff

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com